The study aimed to determine the association of chronic graft-versus-host disease (cGVHD) diagnosis and severity with the development of subsequent neoplasms (SN) and nonmalignant late effects ...(NM-LE) in 2-year disease-free adult survivors following hematopoietic cell transplantation (HCT) for a hematologic malignancy. To do so, we conducted a retrospective analysis of 3884 survivors of HCT for hematologic malignancy in the Center of International Blood and Marrow Transplant Research database. We conducted a landmark analysis at the 2-year post-transplantation date, comparing first SN and NM-LE in survivors with and without cGVHD. The cumulative incidence (CuI) of SN and NM-LE were estimated through 10 years post-HCT in both groups, with death or disease relapse as a competing risk. Cox proportional hazards models were used to evaluate the associations of cGVHD and its related characteristics with the development of SN and NM-LE. The estimated 10-year CuI of SN in patients with GVHD (n = 2669) and patients without cGVHD (n = 1215) was 15% (95% confidence interval CI, 14% to 17%) versus 9% (7.2% to 11%) (P < .001). cGVHD by 2 years post-HCT was independently associated with SN (hazard ratio HR, 1.94; 95% CI, 1.53 to 2.46; P < .0001) with a standardized incidence ratio of 3.2 (95% CI, 2.9 to 3.5; P < .0001). Increasing severity of cGVHD was associated with an increased risk of SN. The estimated 10-year CuI of first NM-LE in patients with and without cGVHD was 28 (95% CI, 26% to 30%) versus 13% (95% CI, 11% to 15%) (P < .001). cGVHD by 2 years post-HCT was independently associated with NM-LE (HR, 2.23; 95% CI, 1.81 to 2.76; P < .0001). Multivariate analysis of cGVHD-related factors showed that increasing severity of cGVHD, extensive grade, having both mucocutaneous and visceral involvement, and receiving cGVHD treatment for >12 months were associated with the greatest magnitude of risk for NM-LE. cGVHD was closely associated with both SN and NM-LE in adult survivors of HCT for hematologic malignancy. Patients identified as having more severe involvement and both mucocutaneous and visceral organ involvement may warrant enhanced monitoring and screening for SNs and NM-LEs. However, caution is warranted when interpreting these results, as patients with cGVHD may have more vigilant post-transplantation health care and surveillance for late effects.
Introduction High risk hematologic malignancies are curable with allogeneic hematopoietic cell transplant (HCT). Haploidentical (haplo) HCT with post-transplant cyclophosphamide (PTCy) has improved ...access to transplant in patients lacking an HLA matched donor. However, traditional reduced-intensity conditioning (RIC) with fludarabine/cyclophosphamide/total body irradiation (TBI) for haplo HCT with PTCy is marred by high rates of relapse. This study seeks to optimize the RIC haplo HCT with PTCy platform in older adults with a slight intensification in conditioning and the use of peripheral blood stem cell (PBSCT) grafts in lieu of bone marrow grafts (BMT). Additionally, tacrolimus was substituted by sirolimus based on prior phase II data suggesting favorable rates of graft-versus-host disease (GVHD) after haplo PBSCT with PTCy (Bejanyan, Blood Adv. 2021). We hypothesized that this approach could successfully reduce the risk of relapse and improve disease-free survival (DFS) without substantially increasing non-relapse mortality (NRM). Methods: This single arm, single center phase II trial of haplo PBSCT used a RIC regimen consisting of Melphalan 70 mg/m 2 IV on day -6, fludarabine 30mg/m 2 IV daily on days -6 to -2, and TBI 200 cGy on day -1 (NCT04191187). Subjects received haplo PBSCT with a target dose of 5 x 10 6 CD34+ cells/kg and capped at 7 x 10 6 CD34+ cells/kg. GVHD prophylaxis consisted of PTCy 50 mg/kg on days +3 and +4, mycophenolate mofetfil (MMF) 1 gram three times daily from days +5 to +35, and sirolimus initiated at a target trough of 8-14 ng/mL on day +5 and tapered off between days +100 and +180. Eligibility criteria required a hematologic malignancy as the indication for allogeneic HCT and either age >55 years or a hematopoietic cell transplant comorbidity index (HCT-CI) > 3. The primary endpoint of this study is DFS with a hypothesis that the experimental regimen would have an 18 month DFS of 60% compared to a historic DFS of 40% and 90% power to reject the null hypothesis. Results: A total of 34 subjects were treated on the trial. The median age was 66 years (range: 31-74 years). The HCT-CI score was > 3 in 41%. Acute myeloid leukemia (AML, 44%) was the predominant indication for transplant followed by myelodysplastic syndromes (MDS, 29%). Nine patients (26%) were from underrepresented racial/ethnic minorities (those other than non-Hispanic white). Five patients (15%) received tacrolimus for GVHD prophylaxis before a protocol amendment changed the regimen to sirolimus for the remaining 29 patients (85%). The median follow-up time for 25 surviving patients was 28.5 months . The trial met the primary endpoint with 18-month DFS of 70.5% (90% CI > 59.1%, p=0.002). We observed no primary graft failure events. Neutrophil engraftment by day 30 was achieved in 30 patients (88%), and platelet engraftment by day 60 was achieved in 28 patients (82%). The cumulative incidence of grade II-IV acute GVHD at day 100 was 11.8% (95% CI: 3.6-25.1%). The cumulative incidence of moderate to severe chronic GVHD at 18 months was 9.1% (95% CI: 2.2-22.0%). At 18 months, the cumulative incidence of NRM was 17.7% (95% CI: 7.0-32.2%) and of relapse was 11.9% (3.7-25.4%). GVHD-free relapse-free survival at 18 months was 61.4% (95% CI: 42.9-75.5%) and the overall survival at 18 months was 73.3% (95% CI: 54.9-85.1%). Conclusion: In this completed phase II trial of fludarabine, melphalan 70 mg/m 2, TBI with haplo PBSCT and PTCy/sirolimus/MMF, the primary endpoint was met with an 18-month DFS that was superior to historical control. This was attributable to low rates of relapse without excessive NRM. Acute and chronic GVHD rates were favorable. Pharmacogenomic and pharmacokinetic correlative data is pending and will be included in the final presentation. These promising results merit further investigation to potentially establish this platform as a new standard approach to RIC haplo PBSCT.
Background: Secondary hematologic malignancies are increasingly recognized due to the rising number of cancer survivors. While therapy related myeloid malignancies have distinct genetic profiles and ...inferior allogeneic stem cell transplantation (alloHCT) outcomes, there is limited data regarding secondary acute lymphoblastic leukemia (sALL). In one report, patients with therapy related ALL had an inferior OS of 23 months after alloHCT compared to primary (pALL) where OS was not reached Saygin et al. 2019. In the past decade, several novel therapies have been FDA approved for adults with B-ALL allowing more patients to achieve molecular remissions prior to alloHCT, therefore, we aimed to examine the role of alloHCT for adults with sALL compared to adults with pALL in a contemporary era. Methods: We identified 247 (n= 25 sALL, n= 223 pALL) patients with ALL who underwent alloHCT at Moffitt Cancer Center from 1/2010 to 12/2022. Matching was performed with a 1:1 nearest neighbor matching on propensity score controlling for age, ALL subtype, MRD status, CR line at transplant, regimen intensity, and lines of therapy received for sALL. Three patients with sALL were excluded from matched analysis due to inability to control for selected covariates. Variable balance was assessed before and after matching. Outcomes measured included overall survival (OS), leukemia free survival (LFS), non-relapse mortality (NRM), and relapse. Survival analysis was evaluated by Kaplan-Meier estimations. Multivariate analysis was performed by Cox regression. Results: After matching, 22 patients in the pALL group and 22 patients in the sALL group were analyzed. The two groups were evenly matched for all baseline characteristics except for donor type ( Table 1 p = 0.019). The majority of patients in both groups were over the age of 40, were diagnosed with Ph(-) B-cell ALL and were transplanted in first complete remission (CR1). Cytogenetic stratification for Ph(-) patients were defined per CIBMTR criteria Lazaryan et al. 2020. In patients with Ph(-) sALL, cytogenetics were classified as adverse (n=4), intermediate ( n=7), favorable (n=2) and were missing in 3 patients. In the sALL group, 59% of patients had an antecedent solid tumor malignancy whereas 36% had a hematologic malignancy with one patient having two prior malignancies. Half of the sALL group (n=11) had chemotherapy exposure for primary malignancy. Median follow up time for the pALL and sALL groups was 76 and 55 months respectively. Compared to the pALL group, the sALL group did not have a significant difference in OS ( Figure 1 p = 0.3). The 2 and 5-year OS of the pALL group was 72% and 67% respectively vs. 60% and 48% in the sALL cohort (p = 0.3). The 2 and 5-year LFS of the pALL cohort was 72% and 52% respectively vs 45% and 45% of the sALL cohort (p = 0.3). Cumulative incidence of NRM (27 % vs. 18%, p=0.7) and relapse (27% vs 32% p = 1.0) were not statistically significant between sALL and pALL groups. In a multivariate analysis performed after matching, there was no associated difference in the OS (p= 0.6) between groups. Conclusion: In this study, we observed no significant difference in OS, LFS, NRM or relapse between sALL patients and pALL patients after controlling for key variables in a matched cohort analysis. Most patients included in this analysis were in complete molecular remission at time of transplant underscoring the prognostic impact of MRD. Despite 50% of the sALL cohort having exposure to prior chemotherapy, few patients had adverse cytogenetics suggesting that cytogenetic risk and MRD, and not only exposure to prior therapy are key prognostic factors for sALL patients undergoing alloHCT. Larger studies are needed to validate these findings. Despite small number of patients, we observe encouraging outcomes for this patient population with traditionally poor outcomes with conventional chemotherapy alone.
Background Despite being the only curative option for many hematologic malignancies, allogeneic hematopoietic cell transplant (HCT) has been plagued by health disparities due to differences in ...access, donor availability, and outcomes across racial and ethnic minority populations (REM) (Gragert, NEJM, 2014). Even when a matched donor is available, HCT outcomes for REM patients are historically worse compared to non-Hispanic white (NHW) patients. (Landry, Stem Cell Investigation, 2021). The development of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has led to increased use of HLA haploidentical (haplo) or mismatched unrelated donors (MMUD) with comparable outcomes to HLA matched HCT (McCurdy, Advances in Hematology, 2015). While PTCy allows for almost every transplant-eligible REM patient to have a suitable donor, there is limited data evaluating whether this transplant platform results in similar outcomes for REM patients compared to NHW patients. The aim of this study was to investigate if disparities in transplant outcomes still exist between REM patients and NHW patients who received an HLA mismatched transplant with PTCy. Methods We retrospectively analyzed 302 consecutive adult patients who underwent haplo or MMUD HCT with PTCy at Moffitt Cancer Center between 2014 and 2022. All endpoints were compared between four groups: NHW, Hispanic-White, Black, and Other (Asian, biracial, or multiracial.) Results In this cohort, 59% (n=178) of patients identified as NHW, 14% (n=41) as Hispanic-White, 16% (n=48) as Black, 7% (n=21) as biracial or multiracial, and 4% (n=11) identified as Asian. Most patients were male (57%). The median age of all patents was 58. The most common indication for transplant was acute myeloid leukemia (48%), myeloablative conditioning (MAC) was utilized in 42%, and 89% received peripheral blood stem cells grafts. REM patients were more likely to be <65 years of age (60% vs 66-90%, p<0.001), female (36% vs 50-54%, p=0.04), and receive MAC conditioning (33% vs 40-71%, p<0.001). Median follow-up was 21 months. In all clinical outcomes, no significant differences were observed between NHW and REM patients. At day 100, the cumulative incidence of Grade II-IV aGVHD was 37% 95% CI 30-44% for NHW patients, 32% 95% CI, 18-46% for Hispanic-White patients, 27% 95% CI, 15-40% for Black patients, and 26% 95% CI, 13-41% for patients of Other races (p= 0.38). The cumulative incidence of moderate to severe cGVHD at 2 years was 21% 95% CI 15-28% for NHW patients, 25% 95% CI, 13-39% for Hispanic-White, 17% 95% CI, 7.8-29% for Black, and 27% 95% CI, 13-42% for patients of Other races (p = 0.80). At 2 years, the probability of relapse was 25% 95% CI 19-32% for NHW patients, 24% 95% CI, 12-39% for Hispanic-White patients, 27% 95% CI, 15-40% for Black patients, and 18% 95% CI, 7.1-33% for patients of Other races (p = 0.97). During the same time interval, non-relapse mortality (NRM) for NHW patients, Hispanic-White patients, Black patients, and patients of Other races were 19% 95% CI, 13-25%, 15% 95% CI, 5.9-27%, 19% 95% CI, 9.4-32%, and 24% 95% CI, 11-40% (p = 0.73), respectively. At 2 years, relapse free survival (RFS) was 56% 95% CI 49-64% for NHW patients, 61% 95% CI, 47-79% for Hispanic-White patients, 54% 95% CI, 41-71% for Black patients, and 58% 95% CI, 43-78% for patients of Other races (p = 0.77). Comparably, OS at 2 years for NHW, Hispanic-White patients, Black patients, and patients of Other races was 64% 95% CI, 57-72%, 72% 95% CI, 60-88%, 53% 95% CI, 40-71%, and 63% 95% CI, 49-83% respectively after two years (p = 0.92). In multivariate analysis, race/ethnicity had no significant impact on incidence of Grade II-IV aGVHD (p= 0.40), moderate/severe cGVHD (p = 0.80), rates of relapse (p = 0.86), NRM (p= 0.77), RFS (p = 0.69), or OS (p = 0.64) (Table). Conclusions These results show that the use of HLA mismatched donor HCT with PTCy achieves comparable clinical outcomes between REM and NHW patients. Our study suggests that PTCy effectively contributes to equitable healthcare in the setting of allogeneic HCT for REM patients.
Standard initial therapy of chronic graft vs. host disease (cGVHD) with glucocorticoids results in suboptimal response. Safety and feasibility of therapy with ofatumumab (1000 mg IV on days 0 and 14) ...and prednisone (1 mg/kg/day) was previously established in our phase I trial (n = 12). We now report the mature results of the phase II expansion of the trial (n = 38). The overall NIH severity of cGVHD was moderate (63%) or severe (37%) with 74% of all patients affected by the overlap subtype of cGVHD and 82% by prior acute cGVHD. The observed 6 month clinician-reported and 2014 NIH-defined overall response rates (ORR = complete + partial response CR/PR) of 62.5% (1-sided lower 90% confidence interval=51.5%) were not superior to pre-specified historic benchmark of 60%. Post-hoc comparison of 6 month NIH response suggested benefit compared to more contemporaneous NIH-based benchmark of 48.6% with frontline sirolimus/prednisone (CTN 0801 trial). Baseline cGVHD features (organ involvement, severity, initial immune suppression agents) were not significantly associated with 6-month ORR. The median time to initiation of second-line therapy was 5.4 months (range 0.9-15.1 months). Failure-free survival (FFS) was 64.2% (95% CI 46.5-77.4%) at 6 months and 53.1% (95% CI 35.8-67.7%) at 12 months, whereas FFS with CR/PR at 12 months of 33.5% exceeded a benchmark of 15% in post-hoc analysis, and was associated with greater success in steroid discontinuation by 24 months (odds ratio 8 (95% CI 1.21-52.7). This single-arm phase II trial demonstrated acceptable safety and potential efficacy of the upfront use of ofatumumab in combination with prednisone in cGVHD. This trial was registered at www.clinicaltrials.gov as #NCT01680965.
•Ofatumumab with glucocorticoid therapy for cGVHD resulted in 62.5% ORR at 6 months and 53% FFS at 12 months.•Safety was observed with ofatumumab plus glucocorticoid for initial therapy.
Display omitted
Background Patients with 2017 European LeukemiaNet (ELN) adverse risk acute myeloid leukemia (AML) are at 40% risk of relapse leading to poor survival after allogeneic hematopoietic cell ...transplantation (allo-HCT) (Hansen TCT 2021, Jimenez BMT 2021). Ex vivo donor-derived gamma delta T cells (GDT) expanded with artificial antigen presented calls (aAPC) are a novel therapy with potent MHC-independent antineoplastic cytotoxicity. An ongoing phase 1/1b study is evaluating the safety and potential efficacy of ex vivo expanded donor GDT after reduced-intensity conditioning (RIC) allo-HCT in patients with ELN adverse risk AML ( NCT05015426). We report on manufacturing, safety, and correlative biology of expanded donor GDT after allo-HCT in the first 5 treated patients (Table 1). Methods The primary endpoint is the maximum-tolerated dose (MTD) of allogeneic donor GDT as a single infusion at day 60 after RIC allo-HCT. Next generation sequencing was used for measurable residual disease (MRD) assessment pre-HCT and post-GDT infusion. Donor GDT collected from the same donor of the allo-HCT were enriched from non-mobilized leukapheresis product by stimulation with zoledronic acid and IL-2 for 7 days followed by alpha beta T cell depletion using the Miltenyi CliniMACS. Enriched GDT (>90% TCRVδ2) were then co-cultured with irradiated aAPCs in Wilson Wolf G-Rex 100MCS over 10 days (Boucher J. Immunother 2023). This single center, investigator-initiated phase 1 trial is testing 3 distinct dose cohorts of infused GDT (5 x 10 6 cells/kg, 2.5 x 10 7 cells/kg, and 1 x 10 8 cells/kg) with acceptable range of 25% margin. A Bayesian optimal interval design is used to guide dose escalation/de-escalation decisions. Results First 3 patients enrolled in dose level 1 (DL1) cohort received GDT dose of 6.25 x 10 6 cells/kg, while last 2 patients enrolled in DL2 cohort received 3.13 x 10 7 cells/kg dose. Dose-limiting toxicities (DLT) were evaluated for 42 days following GDT infusion and no DLT were observed. None of the treated patients experienced cytokine release syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) or graft-versus-host disease (GVHD) during DLT period. Among patients treated on DL1, patient #01 had ASXL1 AML with MRD pos (VAF 43.9%) prior to RIC haploidentical (Haplo) HCT. He is in ongoing complete remission (CR) 9 months post-HCT and has had no GVHD. Patient #02 had MRD pos (VAF 61.7%) AML with TP53 mutation/complex karyotype prior to RIC matched sibling donor allo-HCT. He is in CR and has mild chronic GVHD at 7 months post-HCT. Patient #03 with pre-HCT MRD negRUNX1 AML is in ongoing CR 7 months post-RIC Haplo HCT with no GVHD. At day 28 and day 120 post-GDT, all 3 patients were MRD neg in bone marrow and had 100% bone marrow and peripheral blood leukocyte and granulocyte chimerism. In DL2 cohort, patient #04 with RUNX1 AML and patient #05 with t(9;22) AML both were MRD neg prior to RIC Haplo HCT and remain in CR with no GVHD at 5 and 4 months post-HCT, respectively. At day 28 post-GDT, both patients were MRD neg and had 100% chimerism. Patient #05 had a fall during DLT period in a setting of orthostatic hypotension requiring hospitalization for 24 hours for hydration. This was the only grade 3 adverse event observed in this trial. Serum cytokines analyzed included IL2, IL6, IL15, IFNγ, TNFα, Angiopoietin 1&2, and GM-CSF (Figure 1). We compared results prior and up to 90 days post-GDT infusion and found no significant differences, which can explain no CRS or ICANS events yet observed on this trial. Immunophenotype (TCRVδ2, TCRVδ1, PD1, CTLA4, TIGIT and CD28) of GDT was analyzed in samples of donor apheresis, pre- and post-enrichment, infused GDT product and at days 28 and 90 post-infusion. GDT (TCRVδ2) persisted at day 28 and day 90 post-infusion and expressed low levels of cell surface inhibitory receptors. Conclusion This preliminary interim report demonstrates favorable safety and tolerability of donor GDT therapy with no CRS, ICANS or GVHD in first 5 patients treated in this trial. All these patients with adverse risk AML are in ongoing MRD neg CR following RIC allo-HCT, including 2 pre-HCT MRD pos cases with TP53 AML and AXSL1 AML. Early results of this trial are promising, which provides validation for continued testing of adoptive transfer of ex vivo expanded donor GDT. Updated results of this trial will be presented at the annual conference.
Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), ...with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors. We used the Center for International Blood and Marrow Transplant Research registry to complete a retrospective cohort study in adults with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, who underwent T-cell replete HCT from these 2 donor types (parous female sibling or male URD) between 2000 and 2012. Primary outcomes included grade 2 to 4 acute GVHD (aGVHD), chronic GVHD (cGVHD), and overall survival. Secondary outcomes included disease-free survival, transplant-related mortality, and relapse. In 2813 recipients, patients receiving male URD transplants (n = 1921) had 1.6 times higher risk of grade 2 to 4 aGVHD (P < .0001). For cGVHD, recipient sex was a significant factor, so donor/recipient pairs were evaluated. Female recipients of male URD grafts had a higher risk of cGVHD than those receiving parous female sibling grafts (relative risk RR = 1.43, P < .0001), whereas male recipients had similar rates of cGVHD regardless of donor type (RR = 1.09, P = .23). Donor type did not significantly affect any other end point. We conclude that when available, parous female siblings are preferred over male URDs.
•Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females.•There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.
Display omitted
•Disability as defined by progressive chronic graft-versus-host disease (GVHD) impairments are associated with decline in human activity profile scores and performance status at 18 months.•Worse oral ...scores and patient-reported eye and skin scores are significantly associated with progressive chronic GVHD impairment at 18 months.
Chronic graft-versus-host disease (cGVHD) is a heterogenous syndrome whose symptoms and treatment are often associated with decreases in functional status and quality of life among survivors of transplantation. We explored definitions of cGVHD-related disability and factors associated with disability in cGVHD. We analyzed 371 patients with cGVHD requiring a new systemic therapy with enrollment and 18-month assessments through the Chronic GVHD Consortium, evaluating disability as a composite endpoint including any 1 of 5 impairments previously defined by Fatobene et al 1 (score 2 or 3 keratoconjunctivitis sicca, score 2 or 3 scleroderma, any diagnosis of bronchiolitis obliterans, score 2 or 3 joint/fasciae involvement, or score 3 esophageal stricture requiring dilation). We also evaluated disability, defined as an ≥8-point decline in a human activity profile (HAP) score or a ≥20% decline in Karnofsky Performance Status (KPS) from enrollment to 18 months. At enrollment, 47% of patients had at least 1 of the 5 Flowers disability features, with 50% of this group acquiring additional impairments at 18 months. Of the 197 patients (53%) with no Flowers disability at enrollment, 50% progressed with disability features at 18 months. We found that any progressive Flowers impairment was associated with a decline in HAP/KPS as well as with increased National Institutes of Health severity scores at 18 months. Enrollment mouth scores and patient-reported eye and skin scores were significantly associated with progressive impairment at 18 months. Progressive disability at 18 months did not predict subsequent nonrelapse mortality. Additional studies to define chronic GVHD related-disability and risk factors are needed to develop this important patient-centered outcome.